Golden State Equity Partners Buys 271 Shares of Eli Lilly and Company (NYSE:LLY)

Golden State Equity Partners grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 12.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,481 shares of the company’s stock after buying an additional 271 shares during the period. Golden State Equity Partners’ holdings in Eli Lilly and Company were worth $1,446,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Heritage Financial Services LLC boosted its holdings in Eli Lilly and Company by 5.9% during the fourth quarter. Heritage Financial Services LLC now owns 1,819 shares of the company’s stock worth $1,060,000 after buying an additional 101 shares during the last quarter. Kovack Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 22.5% during the 4th quarter. Kovack Advisors Inc. now owns 4,751 shares of the company’s stock valued at $2,769,000 after purchasing an additional 872 shares in the last quarter. K.J. Harrison & Partners Inc bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $3,325,000. Boyd Watterson Asset Management LLC OH lifted its holdings in shares of Eli Lilly and Company by 12.4% during the 4th quarter. Boyd Watterson Asset Management LLC OH now owns 13,651 shares of the company’s stock valued at $7,957,000 after purchasing an additional 1,510 shares in the last quarter. Finally, Callan Capital LLC lifted its holdings in shares of Eli Lilly and Company by 169.6% during the 4th quarter. Callan Capital LLC now owns 2,828 shares of the company’s stock valued at $1,648,000 after purchasing an additional 1,779 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on LLY shares. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Truist Financial reiterated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.2 %

LLY stock opened at $733.51 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $696.95 billion, a PE ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $380.77 and a 1-year high of $800.78. The business’s 50 day simple moving average is $761.79 and its 200 day simple moving average is $666.67.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.09 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.